Below is a list of grant and award recipients. You may narrow the list down by using the filters below. The list can be sorted by year, last name, and institution. The institution listed reflects the sponsoring institution at the time of grant or award.
Past Recipients Year First Name Last Name Degree Institution Title Grant Amount ($) Subject Area
2019 Stephanie Dixon MD, BS St. Jude Children's Research Hospital Chronic health conditions (CHC) and late mortality in survivors of acute lymphoblastic leukemia (ALL) in the Childhood Cancer Survivor Study.
2019 Nazli Dizman MD City of Hope Infigratinib in upper tract urothelial carcinoma vs urothelial carcinoma of the bladder and association with comprehensive genomic profiling/cell-free DNA results.
2019 Deborah Doroshow MD, PhD Yale University Targeting DNA Damage Repair Mechanisms in IDH1/2 Mutated Intrahepatic Cholangiocarcinomas and Other Solid Tumors 50,000.00
2019 Shaan Dudani MBChB University of Calgary First-line (1L) immuno-oncology (IO) combination therapies in metastatic renal cell carcinoma (mRCC): Preliminary results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).
2019 Narjust Duma MD Mayo Clinic Evaluating unconscious bias: Speaker introductions at an international oncology conference.
2019 Jeffrey Edwards Other Stanford University 8,500.00
2019 Ista Egbeto Other Tufts University School of Medicine 8,500.00
2019 Yasir Elamin MD The University of Texas M.D. Anderson Cancer Center Optimizing targeted therapy for HER2 mutant non-small cell lung cancer (NSCLC) and other solid tumors 200,000.00
2019 Lawson Eng MD Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre Impact of health behavior change on health utility (HU) and financial toxicity in head and neck cancer (HNC) survivors.
2019 Taimy Falcon-Rodriguez MD San Juan Bautista School of Medicine 8,500.00
2019 Kelly Faulk MD University of Colorado Assessment of enrollment characteristics for Children’s Oncology Group (COG) upfront therapeutic clinical trials 2004-2015.
2019 Roberto Ferrara MD Istituto Nazionale dei Tumori Fast-progression (FP), hyper-progression (HPD) and early deaths (ED) in advanced non-small cell lung cancer (NSCLC) patients (pts) upon PD-(L)-1 blockade (IO).
2019 Arlindo Ferreira MD, MSc Institut Gustave Roussy Differential impact of endocrine therapy (ET) and chemotherapy (CT) on quality of life (QoL) of 4,262 breast cancer (BC) survivors: A prospective patient-reported outcomes (PRO) analysis.
2019 Stefanie Fischer MD University of Manchester Outcome of men with relapses after adjuvant BEP for clinical stage I nonseminoma.
2019 Charalampos Floudas MD, DMSc, MS National Cancer Institute Combined immune checkpoint inhibition (ICI) with tremelimumab and durvalumab in patients with advanced hepatocellular carcinoma (HCC) or biliary tract carcinomas (BTC).
2019 Adriana Fonseca MD The Hospital for Sick Children Outcome of children with malignant germ cell tumors by response status at the end of induction chemotherapy.
2019 Elisa Fontana MD The Institute of Cancer Research and The Royal Marsden Hospital Characterisation of chemoradiation-induced changes in immune cells and targets for personalized therapy in locally advanced rectal cancer (LARC).
2019 Deborah Forst MD Massachusetts General Hospital Psychological Intervention for Caregivers of Patients with Malignant Gliomas 200,000.00
2019 Jason Frankel MD Virginia Mason Medical Center Contemporary trends in treatment for low-risk prostate cancer.
2019 MARIA FRANZOI MD Hospital de Clinicas de Porto Alegre
2019 Jacquelyne Gaddy MD University at Buffalo 1,500.00
2019 Adam Gadzinski MD, MS University of Washington Telehealth to improve access to urological cancer care among rural patients 50,000.00
2019 Adriana Gamboa MD Emory University Duodenal neuroendocrine tumors: Somewhere between the pancreas and small bowel?
2019 Sara Gandolfi MD Dana-Farber Cancer Institute Enhancing the response of multidrug-resistant myeloma cells to natural killer (NK) cells 50,000.00
2019 Yasser Ged MBBS, MRCP Memorial Sloan Kettering Cancer Center Alterations in DNA damage repair (DDR) genes and outcomes to systemic therapy in 225 immune-oncology (IO) versus tyrosine kinase inhibitor (TKI) treated metastatic clear cell renal cell carcinoma (mccRCC) patients (pts).
2019 Ehsan Ghorani MBBS University College London Cancer Institute Imbalance between early and late differentiated intra-tumour CD4 T cells is associated with mutational burden in non-small cell lung cancer.
2019 Arunangshu Ghoshal MBBS, MD Tata Memorial Hospital
2019 Smith Giri MBBS Yale School of Medicine Chromosome 1 abnormalities and clinical outcomes in multiple myeloma in the era of novel agents.
2019 Ashley Graul MD University of Pennsylvania Effect of patient education on palliative care knowledge and acceptability of outpatient palliative care service among gynecologic oncology patients.
2019 Angela Green MD, MSc Memorial Sloan Kettering Cancer Center Utility of a Population-Based Data Source to Examine National Cancer Clinical Trial Participation 50,000.00
2019 Katie Greenzang MD Dana-Farber Cancer Institute Enhancing Information, Preparation, and Shared Decision-Making about Long-term Outcomes of Pediatric Cancer and its Treatment 200,000.00
2019 Robin Guo MD Memorial Sloan Kettering Cancer Center MET inhibitor resistance in patients with MET exon 14-altered lung cancers.
2019 Sumit Gupta MD, PhD Hospital for Sick Children Impact of asparaginase discontinuation on outcome in childhood ALL: A report from the children’s oncology group (COG).
2019 Andrew Hahn MD University of Utah Genomic landscape of metastatic hormone sensitive prostate cancer (mHSPC) vs. metastatic castration-refractory prostate cancer (mCRPC) by circulating tumor DNA (ctDNA).
2019 Evan Hall MD, MPhil Stanford University Economic analysis of alternative pembrolizumab and nivolumab dosing strategies at an academic cancer center.
2019 Anis Hamid MBBS Dana-Farber Cancer Institute Genomic predictors of benefit of docetaxel (D) and next-generation hormonal therapy (NHT) in metastatic castration resistant prostate cancer (mCRPC).
2019 Glenn Hanna MD Dana-Farber Cancer Institute Circulating human papillomavirus (HPV) cell-free (cf)DNA in head and neck cancer 200,000.00
2019 Ross Harrison MD The University of Texas M.D. Anderson Cancer Center Cost-effectiveness analysis of laparoscopic disease assessment in ovarian cancer.
2019 Jessica Hawley MD Columbia University Medical Center Augmenting the ADT-induced immune infiltrate in metastatic hormone-sensitive prostate cancer with PD-1 blockade and docetaxel 50,000.00
2019 Caroline Hesko MD, MPH, BS University of Chicago Neurocognitive outcomes in adult survivors of neuroblastoma: A report from the Childhood Cancer Survivor Study.
2019 Joseph Hiatt MD, PhD Fred Hutchinson Cancer Research Center Role of the transcriptional repressor REST in shaping the immunologic tumor microenvironment in small cell lung cancer 50,000.00
2019 Won Jin Ho MD, MS Johns Hopkins University Role of PTPN22 in Antitumor Immune Response 50,000.00
2019 Evthokia Hobbs MD The University of Texas M.D. Anderson Cancer Center Tumor immune microenvironment (TiME) changes by multiplex IF staining in a pilot study of neoadjuvant talazoparib for early-stage breast cancer patients with a BRCA mutation.
2019 Joshua Horton MD Medical University of South Carolina Neoadjuvant presurgical PD-1 inhibition in oral cavity squamous cell carcinoma.
2019 Antony Hsieh MD University of Pennsylvania Function and therapeutic targeting of MYBBP1A in pancreatic cancer 50,000.00
2019 Dennis Hsu MD Memorial Sloan Kettering Cancer Center Characterization and Exploitation of preferred tRNAs in Lung Adenocarcinoma 50,000.00
2019 Li-Wen Huang MD University of California, San Francisco Understanding the Relationship Between Frailty and Cognitive Decline After Allogeneic Stem Cell Transplantation in Older Adults 50,000.00
2019 Liang Huang MD, PhD Huazhong University of Science and Technology Efficacy and safety of CAR19/22 t-cell “cocktail” therapy in patients with refractory/relapsed b-cell non-Hodgkin lymphoma.
2019 Melissa Huynh MD Brigham and Women's Hospital Associations of cell cycle genetic variants with aggressive prostate cancer in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial.